Brokers Issue Forecasts for Acasti Pharma Inc.’s Q1 2025 Earnings (NASDAQ:ACST)

Acasti Pharma Inc. (NASDAQ:ACST) – Equities researchers at HC Wainwright issued their Q1 2025 earnings estimates for Acasti Pharma in a note issued to investors on Monday, July 1st. HC Wainwright analyst O. Livnat anticipates that the biopharmaceutical company will earn ($0.28) per share for the quarter. The consensus estimate for Acasti Pharma’s current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Acasti Pharma’s Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.28) EPS, FY2028 earnings at $0.24 EPS and FY2029 earnings at $1.64 EPS.

Acasti Pharma (NASDAQ:ACST) last issued its quarterly earnings results on Friday, June 21st. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.30.

Acasti Pharma Price Performance

ACST stock opened at $2.92 on Tuesday. Acasti Pharma has a twelve month low of $1.72 and a twelve month high of $3.84. The firm has a market cap of $27.45 million, a price-to-earnings ratio of -2.03 and a beta of 1.55. The business’s fifty day simple moving average is $2.93 and its two-hundred day simple moving average is $2.94.

About Acasti Pharma

Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.